---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-050528"
form_type: "8-K"
ticker: "HYPD"
cik: "0001682639"
company_name: "HYPERION DEFI, INC."
filed_at: "2025-05-19T23:59:59+00:00"
generated_at: "2026-05-21T01:49:00.944582+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Eyenovia Reports Q1 2025 Financial Results, Provides Merger and Optejet Development Update

## Summary
- Net loss narrowed to $3.5 million ($1.59 per share) versus $10.9 million ($18.75 per share) in Q1 2024.
- Continuing merger negotiations with Betaliq; binding exclusivity extended to June 7, 2025.
- Optejet user-filled device on track to file for FDA device approval in September 2025.
- Cash burn reduced by approximately 70% versus prior year; debt restructuring with Avenue Capital defers payments to October 2025.
- Unrestricted cash and equivalents totaled $3.9 million as of March 31, 2025.

## SEC filing metadata
- accession: 0001104659-25-050528
- form_type: 8-K
- ticker: HYPD
- cik: 0001682639
- company_name: HYPERION DEFI, INC.
- filed_at: 2025-05-19T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1682639/000110465925050528/0001104659-25-050528-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1682639/000110465925050528/tm2515543d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-050528
- JSON: https://secwatch.observer/filing/0001104659-25-050528.json
- Plain text: https://secwatch.observer/filing/0001104659-25-050528.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.